Business Context and Reporting Period
Prelude Therapeutics Inc. (PRLD) filed this Form 8-K on September 18, 2025. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market. The filing addresses a specific regulatory event regarding the company's listing status.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the resolution of a listing compliance issue:
- Previous Status: On March 27, 2025, Nasdaq notified the company of non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) as the stock price had fallen below $1.00 per share.
- Current Status: On September 18, 2025, Nasdaq notified the company that it has regained compliance with the Minimum Bid Price Requirement.
- Outcome: The matter regarding the listing deficiency is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose new risks or contingencies beyond the previously noted listing deficiency, which has now been resolved.
Investor Verification Checklist
- Verify the current trading price of PRLD to confirm it remains above the $1.00 minimum bid price threshold.
- Review the company's most recent 10-Q or 10-K filings for actual financial performance data, as this 8-K contains none.
- Monitor future Nasdaq communications to ensure no new compliance issues arise.